(-0.41%) 5 046.25 points
(-0.18%) 37 923 points
(-0.74%) 17 442 points
(-1.50%) $80.70
(-2.81%) $1.935
(-0.20%) $2 298.40
(0.14%) $26.69
(0.12%) $949.30
(0.02%) $0.937
(0.19%) $11.12
(0.04%) $0.801
(0.01%) $93.46
Live Chart Being Loaded With Signals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases...
Stats | |
---|---|
今日成交量 | 1 479.00 |
平均成交量 | 1 477.00 |
市值 | 1.79M |
EPS | $0 ( 2023-09-29 ) |
Last Dividend | $0.150 ( 2024-01-19 ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.12 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-21 | Mcbarron Paul | Buy | 1 886 | Common Stock |
2023-12-21 | Mcbarron Paul | Buy | 1 886 | Warrants (right to buy) |
2023-12-21 | Rombotis Spiro George | Buy | 6 070 | Common Stock |
2023-12-21 | Rombotis Spiro George | Buy | 6 070 | Warrants (right to buy) |
2023-06-30 | Rombotis Spiro George | Buy | 110 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 4 220 559 | Sell: 12 |
Cyclacel Pharmaceuticals 财务报表
Annual | 2023 |
营收: | $420 000 |
毛利润: | $389 000 (92.62 %) |
EPS: | $-26.51 |
FY | 2023 |
营收: | $420 000 |
毛利润: | $389 000 (92.62 %) |
EPS: | $-26.51 |
FY | 2022 |
营收: | $0 |
毛利润: | $-32 000.00 (0.00 %) |
EPS: | $-32.23 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-9.93 |
Financial Reports:
No articles found.
Cyclacel Pharmaceuticals Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0.150 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.150 | 2006-01-18 |
Last Dividend | $0.150 | 2024-01-19 |
Next Dividend | $0 | N/A |
Payout Date | 2024-02-01 | |
Next Payout Date | N/A | |
# dividends | 59 | -- |
Total Paid Out | $8.85 | -- |
Avg. Dividend % Per Year | 5.36% | -- |
Score | 4.27 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 5.00 | |
Div. Directional Score | 0.127 | -- |
Year | Amount | Yield |
---|---|---|
2006 | $0.600 | 14.50% |
2007 | $0.600 | 11.20% |
2008 | $0.600 | 12.60% |
2009 | $0.150 | 7.89% |
2010 | $0 | 0.00% |
2011 | $0.300 | 7.71% |
2012 | $0 | 0.00% |
2013 | $0.600 | 6.67% |
2014 | $0.750 | 8.13% |
2015 | $0.450 | 6.96% |
2016 | $0.600 | 15.30% |
2017 | $0.600 | 9.68% |
2018 | $0.600 | 9.16% |
2019 | $0.600 | 9.60% |
2020 | $0.450 | 9.00% |
2021 | $0.600 | 8.53% |
2022 | $0.600 | 9.68% |
2023 | $0.600 | 5.19% |
2024 | $0.150 | 0.91% |
The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -53.86 | 1.500 | -10.00 | -10.00 | [0 - 0.5] |
returnOnAssetsTTM | -2.57 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -3.10 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | -0.00889 | -1.000 | -0.0889 | 0.0889 | [0 - 1] |
currentRatioTTM | 0.912 | 0.800 | -0.439 | -0.351 | [1 - 3] |
quickRatioTTM | 0.773 | 0.800 | -0.157 | -0.126 | [0.8 - 2.5] |
cashRatioTTM | 0.414 | 1.500 | 8.81 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.00420 | -1.500 | 9.93 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -18.87 | 2.00 | -9.44 | -10.00 | [0 - 20] |
debtEquityRatioTTM | 0.0610 | -1.500 | 9.76 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.0580 | 1.000 | -2.37 | -2.37 | [0.2 - 0.8] |
operatingProfitMarginTTM | -61.55 | 1.000 | -10.00 | -10.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -435.46 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.0477 | 0.800 | -3.02 | -2.41 | [0.5 - 2] |
Total Score | -4.75 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.0800 | 1.000 | -0.109 | 0 | [1 - 100] |
returnOnEquityTTM | -3.10 | 2.50 | -10.00 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -18.87 | 2.00 | -6.29 | -10.00 | [0 - 30] |
payoutRatioTTM | -0.00889 | 1.500 | -0.0889 | 0.0889 | [0 - 1] |
pegRatioTTM | -0.00282 | 1.500 | -3.35 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | -38.36 | 1.000 | -10.00 | 0 | [0.1 - 0.5] |
Total Score | -4.53 |
Cyclacel Pharmaceuticals
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。